TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02789605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacilor
Description: Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
Study: NCT04249713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Interleukin 17 Receptor A Antagonist
Study: NCT04433078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 MG Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet
Study: NCT02961569

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sputum collection for acid fast bacilli
Description: spontaneous or post fiberoptic bronchoscopy sputa
Study: NCT01164098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Induction therapy
Study: NCT01890811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost High Protein
Description: Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
Study: NCT01533441

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin K2
Description: 4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
Study: NCT01624935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy
Description: interpersonal psychotherapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interpersonal psychotherapy
Description: interpersonal psychotherapy
Study: NCT01871025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital and home exercise training
Description: Hospital exercise training (aerobic and strength) followed by exercise training

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
Study: NCT02125344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-pegylated liposomal doxorubicin
Description: 20 mg/m2, i.V. 18 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 80mg/m² 18 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m² 18 times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 150mg/m² every 2 weeks for 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 2000 mg/m² every 2 weeks for 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
Study: NCT02819505

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Study: NCT02125344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
Study: NCT02819505

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03388892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)
Description: Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
Study: NCT03941691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Absorbable VSD Occlusion System
Description: Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VSD Occluder
Description: Under echocardiography guided treatment of VSD with commercially available occluder.
Study: NCT01478893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-068
Description: Sub-cutaneous injection, multiple dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sub-cutaneous injection, multiple dose
Study: NCT03388892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain Balloon
Description: Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
Study: NCT03975153

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: guselkumab
Description: Treatment at the FDA-approved psoriasis dosing for 20 weeks
Study: NCT00609752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alicalm (polymeric liquid formula)
Description: Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks.
Study: NCT03067792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil, irinotecan and leucovorin
Description: In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
Study: NCT04149496

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: in vitro maturation of oocytes
Description: Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
Study: NCT04473781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Radiation Therapy
Description: Undergo interstitial brachytherapy
Study: NCT01584258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatectomy
Description: Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Prostate Radiotherapy
Description: Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Prostate Radiotherapy
Description: Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate SBRT
Description: Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate SBRT
Description: Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate SBRT
Description: Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
Study: NCT03807115

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of stroke mobility guidelines
Description: Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
Study: NCT04599049

Intervention type: OTHER
Group type: OTHER
Intervention: six sessions of online classes and virtual training day camps through Zoom in two days
Description: The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively.
Study: NCT01511432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir formulation A
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir formulation A
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation B
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation B
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation C
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation C
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation D
Description: A single 1125-mg dose administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir Formulation D
Description: A single 1125-mg dose administered orally
Study: NCT00895648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv infusion every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² iv infusion every 3 weeks for 3 cycles
Study: NCT00276549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02465346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSU-based stroke management
Description: Prehospital stroke treatment with a mobile stroke unit

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control stroke management
Description: Conventional stroke management
Study: NCT02196987

Intervention type: OTHER
Intervention: Urination during urethral catheterisation
Description: Requesting the patient to urinate while inserting urethral catheter

Intervention type: OTHER
Intervention: Urethral catheterisation, without further guidance
Description: Lying, inserting urethral catheter, without further guidance from health care professional
Study: NCT04266106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SuperBio probiotic
Description: One capsule po BID for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule po BID for 28 days
Study: NCT01809925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium fiber 6.8g
Description: Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
Study: NCT04563702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1
Description: non replicating Ad5 adjuvanted oral tableted vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-CoV2-1
Description: non replicating Ad5 adjuvanted oral tableted vaccine
Study: NCT01809925

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
Study: NCT01608282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPEN website
Description: The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
Study: NCT01889888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submucosal injection of ADRC
Description: Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
Study: NCT04511819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod oral tablet
Description: Losmapimod will be administered with food when possible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be administered with food when possible.
Study: NCT02297113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade
Description: conventional endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Study: NCT03215043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriocitrin
Description: The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
Study: NCT04929613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training
Description: 2.5-day intensive MBRT training sessions.
Study: NCT01033487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral inhaled formulation, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Description: oral inhaled formulation, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose PF-03635659
Description: oral inhaled formulation, single dose, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Dose PF-03635659
Description: oral inhaled formulation, single dose, mid dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose PF-03635659
Description: oral inhaled formulation, single dose, high dose
Study: NCT03355794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral capsule or liquid formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral capsule or liquid formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral capsule or liquid formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Oral capsule or liquid formula

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Oral tablets or dispersible tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Oral tablets or dispersible tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Oral tablets or dispersible tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Oral tablets or dispersible tablets
Study: NCT02701192

Intervention type: OTHER
Intervention: Coccygectomy
Description: Patient receiving coccygectomy surgery.
Study: NCT01344252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: We will made anesthesia with topical lidocaine and compared with subtenon anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
Study: NCT03031548

Intervention type: DEVICE
Intervention: Point-of-care ultrasound exam
Description: No intervention

Intervention type: RADIATION
Intervention: Reposition ETT
Description: ETT will be repositioned based on CXR by fluoroscopy
Study: NCT02677220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI532 cochlear implant
Study: NCT01705548

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery
Description: Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
Study: NCT00276549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT01848639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Study: NCT04613505

Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.

Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.

Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.

Intervention type: BEHAVIORAL
Intervention: Same day consent questionnaire
Description: A questionnaire (yet to be developed) will be administered to participants.
Study: NCT02471911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Description: KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Rituximab 375 mg/m2 on D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV Etoposide 100 mg/m2 on D1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Carboplatin AUC 5 on D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IV Ifosfamide 5 g/m2 on D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5